✦ LIBER ✦

Is entecavir ideal for the treatment of lamivudine-refractory chronic hepatitis B?

✍ Scribed by Chien-Wei Su; Jaw-Ching Wu; Shou-Dong Lee

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 53 KB
Volume: 48
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22520

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adefovir-based combination therapy with

Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B

✍ Soon Sun Kim; Jae Youn Cheong; Dami Lee; Myoung Hee Lee; Sun Pyo Hong; Soo-Ok Ki 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

This study evaluated the efficacy of adefovir (ADV) plus lamivudine (LAM) or ADV add-on therapy for patients with entecavir (ETV)-refractory hepatitis B infection. Twenty-nine ETVresistant and 8 patients with suboptimal response to ETV were enrolled. Twenty-seven patients received ADV þ LAM therapy

Lamivudine treatment for children with i

Lamivudine treatment for children with interferon refractory chronic hepatitis B

✍ Nurten Koçak; İnci Nur Saltik; Hasan Özen; Aysel Yüce; Figen Gürakan 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 28 KB 👁 1 views

Entecavir therapy for lamivudine-refract

Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks

✍ Morris Sherman; Cihan Yurdaydin; Halis Simsek; Marcelo Silva; Yun-Fan Liaw; Vino 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 322 KB 👁 1 views

for the AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group In hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who were refractory to current lamivudine therapy, switching to entecavir was superior to continued lamivudine at week 48 for histologic i

Entecavir treatment for chronic hepatiti

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV

Combined Interferon and Lamivudine Thera

Combined Interferon and Lamivudine Therapy: Is This The Treatment of Choice for Patients With Chronic Hepatitis B Virus Infection?

✍ Norah A. Terrault 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB 👁 2 views

Corrections: Entecavir treatment for chr

Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

In the August 2011 issue of HEPATOLOGY, in the article entitled ''Carcinogen-induced hepatic tumors in KLF6þ/À mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation'' (volume 54, pages 522-531), Dr.